JP2014505008A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505008A5
JP2014505008A5 JP2013527140A JP2013527140A JP2014505008A5 JP 2014505008 A5 JP2014505008 A5 JP 2014505008A5 JP 2013527140 A JP2013527140 A JP 2013527140A JP 2013527140 A JP2013527140 A JP 2013527140A JP 2014505008 A5 JP2014505008 A5 JP 2014505008A5
Authority
JP
Japan
Prior art keywords
composition
administration
narubutsu
set narubutsu
perillylalcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527140A
Other languages
English (en)
Japanese (ja)
Other versions
JP5797755B2 (ja
JP2014505008A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/049392 external-priority patent/WO2012027693A2/en
Publication of JP2014505008A publication Critical patent/JP2014505008A/ja
Publication of JP2014505008A5 publication Critical patent/JP2014505008A5/ja
Application granted granted Critical
Publication of JP5797755B2 publication Critical patent/JP5797755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527140A 2010-08-27 2011-08-26 Ｐｏｈ誘導体を含む医薬組成物 Active JP5797755B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37774710P 2010-08-27 2010-08-27
US61/377,747 2010-08-27
US201161471402P 2011-04-04 2011-04-04
US61/471,402 2011-04-04
PCT/US2011/049392 WO2012027693A2 (en) 2010-08-27 2011-08-26 Pharmaceutical compositions comprising poh derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015006736A Division JP5982507B2 (ja) 2010-08-27 2015-01-16 Ｐｏｈ誘導体を含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2014505008A JP2014505008A (ja) 2014-02-27
JP2014505008A5 true JP2014505008A5 (enExample) 2014-10-16
JP5797755B2 JP5797755B2 (ja) 2015-10-21

Family

ID=45724091

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013527140A Active JP5797755B2 (ja) 2010-08-27 2011-08-26 Ｐｏｈ誘導体を含む医薬組成物
JP2015006736A Active JP5982507B2 (ja) 2010-08-27 2015-01-16 Ｐｏｈ誘導体を含む医薬組成物
JP2016151115A Active JP6431009B2 (ja) 2010-08-27 2016-08-01 Ｐｏｈ誘導体を含む医薬組成物
JP2018206892A Pending JP2019052154A (ja) 2010-08-27 2018-11-01 Ｐｏｈ誘導体を含む医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015006736A Active JP5982507B2 (ja) 2010-08-27 2015-01-16 Ｐｏｈ誘導体を含む医薬組成物
JP2016151115A Active JP6431009B2 (ja) 2010-08-27 2016-08-01 Ｐｏｈ誘導体を含む医薬組成物
JP2018206892A Pending JP2019052154A (ja) 2010-08-27 2018-11-01 Ｐｏｈ誘導体を含む医薬組成物

Country Status (8)

Country Link
US (12) US9499461B2 (enExample)
EP (5) EP2898883B1 (enExample)
JP (4) JP5797755B2 (enExample)
CN (3) CN103168018B (enExample)
BR (1) BR112013004698B1 (enExample)
DK (1) DK3685835T3 (enExample)
ES (4) ES3034958T3 (enExample)
WO (1) WO2012027693A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054333A1 (en) * 2013-10-08 2015-04-16 Neonc Technologies, Inc. Methods of treating cancer using compositions comprising perillyl alcohol derivative
US9913838B2 (en) 2010-08-27 2018-03-13 Neonc Technologies, Inc. Methods of treating cancer using compositions comprising perillyl alcohol derivative
EP2898883B1 (en) 2010-08-27 2016-11-23 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
US20160038600A1 (en) * 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
WO2018005994A1 (en) * 2016-07-01 2018-01-04 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
US11147809B2 (en) 2010-08-27 2021-10-19 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
DK2651864T3 (en) 2010-12-17 2016-09-05 Neonc Tech Inc Methods and devices for use of isoperillylalkohol
BR112014006153A2 (pt) 2011-09-16 2020-12-01 Nanocare Technologies, Inc. composição farmacêutica, e, método para tratar um distúrbio
BR112014012180A2 (pt) * 2011-11-21 2017-05-30 Neonc Tech Inc composições farmacêuticas compreendendo álcool perilílico, álcool iso-perilílico e seus derivados enriquecidos de deutério
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물
WO2016064959A1 (en) * 2014-10-21 2016-04-28 Odin Biotech Two-layer ocular implant comprising a tyrosine kinase inhibitor
TWI677342B (zh) * 2014-10-27 2019-11-21 美商尼翁客技術公司 紫蘇醇衍生物於製備用於治療鼻咽癌的醫藥組成物之用途
WO2016109779A1 (en) * 2014-12-31 2016-07-07 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof
US9522918B2 (en) 2015-02-12 2016-12-20 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
US10562901B2 (en) 2016-09-22 2020-02-18 The University Of Massachusetts Temozolomide compounds, polymers prepared therefrom, and method of treating a disease
US10858305B2 (en) * 2016-11-30 2020-12-08 Neonc Technologies, Inc. Perillyl alcohol-3-bromopyruvate conjugate and methods of treating cancer
WO2018122724A1 (en) * 2016-12-27 2018-07-05 Granules India Limited Temozolomide process
US11559508B2 (en) * 2017-04-19 2023-01-24 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives and methods of use
WO2019014420A1 (en) * 2017-07-12 2019-01-17 Azhc, Llc COMPOSITIONS AND METHODS FOR REDUCING MEDICATION ERRORS
EP3672609A4 (en) * 2017-08-24 2021-08-11 The Board of Trustees of the Leland Stanford Junior University SINGLE-PENAL ALDEHYDE DEHYDROGENASE 3A1 ACTIVATORS AND METHODS OF USE THEREOF
CN107789349A (zh) * 2017-12-01 2018-03-13 新乡医学院 治疗阿尔海默氏综合症的药物组合物及其应用
JP7325425B2 (ja) * 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
CN112469401A (zh) * 2018-06-15 2021-03-09 尼昂克技术公司 包含poh衍生物的药物组合物
US20210244820A1 (en) * 2018-06-15 2021-08-12 Neonc Technologies, Inc. Pharmaceutical compositions comprising poh derivatives
EP4243794A4 (en) * 2020-11-12 2025-03-26 Neonc Technologies, Inc. TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL
WO2022178218A1 (en) 2021-02-19 2022-08-25 Mevion Medical Systems, Inc. Gantry for a particle therapy system
WO2022221759A1 (en) * 2021-04-16 2022-10-20 Neonc Technologies, Inc. Pharmaceutical compositions comprising poh derivatives
CN117460496A (zh) * 2021-04-28 2024-01-26 尼昂克技术公司 紫苏醇用于增强左旋多巴递送的用途
TWI849808B (zh) 2022-03-18 2024-07-21 共信醫藥科技股份有限公司 藥物組成物及化療劑用於製備治療癌症之藥物的用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508602A (en) 1974-04-01 1978-04-26 Bush Boake Allen Ltd Production of esters of perillyl alcohol
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
US4272441A (en) * 1980-03-13 1981-06-09 Fmc Corporation Preparation of carbamates
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US6313176B1 (en) 1989-10-17 2001-11-06 Everett J. Ellinwood, Jr. Dosing method of administering deprenyl via intraoral administration or inhalation administration
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1992022286A1 (en) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
DE69232034T2 (de) 1991-12-18 2002-06-06 Minnesota Mining And Mfg. Co., Saint Paul Aerosolzusammensetzungen für Arzneimittelsuspensionen
US5587402A (en) 1992-04-09 1996-12-24 Wisconsin Alumni Research Foundation Regression of mammalian leukemia cell tumors
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19541963A1 (de) * 1995-11-10 1997-05-15 Henkel Kgaa Carbonylverbindungen
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6143227A (en) 1997-07-30 2000-11-07 Visteon Global Technologies, Inc. Method for injection molding an article having film covered flanges
US5994598A (en) 1998-01-15 1999-11-30 Doyle E. Chastain Method of preparing perillyl alcohol and perillyl acetate
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
KR20010042816A (ko) 1998-04-18 2001-05-25 그레이엄 브레레톤, 레슬리 에드워즈 에어로졸 제약 제형
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
US6133324A (en) 1998-05-07 2000-10-17 The Regents Of The University Of California Use of perillyl alcohol in organ transplantation
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
PT1169019E (pt) 1999-04-14 2003-07-31 Glaxo Group Ltd Formulacao farmaceutica em aerossol
JP5118792B2 (ja) 2000-01-14 2013-01-16 株式会社フコク ダンパおよびその製造方法
US20020010128A1 (en) 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US6378819B1 (en) 2000-08-21 2002-04-30 William W. Johnson Implement mounting assembly for attachment to a vehicle
US20050250854A1 (en) 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US7056491B2 (en) 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
WO2002076404A2 (en) * 2001-03-23 2002-10-03 Protarga, Inc. Fatty alcohol drug conjugates
US20060104997A1 (en) * 2001-12-11 2006-05-18 Constantinides Panayiotis P Monoterpene compositions and uses thereof
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US6994083B2 (en) 2001-12-21 2006-02-07 Trudell Medical International Nebulizer apparatus and method
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
WO2004008101A2 (en) * 2002-07-12 2004-01-22 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
DE10308278B4 (de) * 2003-02-26 2007-07-05 Dr. André Rieks, Labor für Enzymtechnologie GmbH Antimikrobielle Wirkstoffe gegen Bakterien, Hefen und Schimmelpilze
GB2414395B (en) 2003-03-26 2007-10-31 Kringle Pharma Inc Asthma preparation
US7015349B2 (en) * 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
EP1656133A4 (en) 2003-08-15 2008-10-29 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
KR20070051258A (ko) 2004-06-23 2007-05-17 호프만 로버트 에프 표적화되는 산화적 치료 제형의 화상 치료에서의 용도
WO2006065126A2 (en) 2004-10-14 2006-06-22 Plant Research International B.V. Terpene hydroxylation
US7483173B2 (en) 2005-03-10 2009-01-27 Kabushiki Kaisha Toshiba Data processor having a synchronizing function of a plurality of chips
US7725813B2 (en) 2005-03-30 2010-05-25 Arizan Corporation Method for requesting and viewing a preview of a table attachment on a mobile communication device
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
WO2007008897A1 (en) 2005-07-12 2007-01-18 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Microwave-induced ion cleaving and patternless transfer of semiconductor films
WO2007025249A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
DE202006011065U1 (de) 2006-07-18 2006-11-02 Testo Ag Messanordnung zur Strömungsmessung in einem Kanal
CA2694166A1 (en) 2006-07-31 2008-02-07 Bio-Tree Systems, Inc. Blood vessel imaging and uses therefor
EP2081565A2 (en) 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
US20110178062A1 (en) * 2007-03-01 2011-07-21 Allison Brett D Indole and benzothiophene compounds as modulators of the histamine h3 receptor
EP4074704A1 (en) 2007-04-11 2022-10-19 CanBas Co., Ltd. Quinoline compounds with anti-cancer activity
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
EP2042167A1 (en) 2007-09-26 2009-04-01 Aisa Therapeutics Use of a monoterpene to induce tissue repair
US7745670B2 (en) 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
AU2009248914A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
US8058469B2 (en) 2008-11-03 2011-11-15 Sabic Innovative Plastics Ip B.V. Method for making carbamates, ureas and isocyanates
WO2010091198A1 (en) * 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes
EP2898883B1 (en) * 2010-08-27 2016-11-23 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
US9651554B2 (en) 2010-09-24 2017-05-16 The Methodist Hospital Research Institute Molecular diagnostic methods for predicting brain metastasis of breast cancer
US9522918B2 (en) 2015-02-12 2016-12-20 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives

Similar Documents

Publication Publication Date Title
JP2014505008A5 (enExample)
JP2014507391A5 (enExample)
JP7229162B2 (ja) 癌の治療に対する併用療法
JP2012530779A5 (enExample)
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
NI201300082A (es) Métodos de tratamiento del cáncer utilizando 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona.
JP2020500862A5 (enExample)
RU2015143610A (ru) Лечение катаплексии
JP2020514316A5 (enExample)
JP2016534063A5 (enExample)
JP2015519347A5 (enExample)
PH12015500212A1 (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoixoindolin-2-yl)piperidine-2,6-dione
MX2010005342A (es) Compuestos indola y metodos para tratar el dolor visceral.
JP2015528491A5 (enExample)
JP2017125036A (ja) アンドロゲン受容体調節薬のエステル誘導体およびそれらの使用のための方法
JP2020105214A (ja) ペリリルアルコール誘導体を含む医薬組成物
Zhang et al. Research advances in the clinical application of esketamine
WO2012027693A3 (en) Pharmaceutical compositions comprising poh derivatives
JP2015529234A5 (enExample)
RU2012101947A (ru) Способы лечения и профилактики усталости
JP2010521446A5 (enExample)
BR112013015107B1 (pt) Composição farmacêutica, uso de um álcool isoperílico ou um carbamato de álcool isoper ílico e processo para produzir um carbamato de álcool isoperílico
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
JP2015502352A5 (enExample)
Gan et al. Effect of esketamine on postoperative depressive symptoms in patients undergoing thoracoscopic lung cancer surgery: a randomized controlled trial